^
    2d
    BGB-11417-303: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) (clinicaltrials.gov)
    P3, N=630, Recruiting, BeOne Medicines
    Trial initiation date
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    11d
    BGB-11417-304: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • sonrotoclax (BGB-11417)
    11d
    BGB-11417-204: A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, BeOne Medicines | Trial completion date: Jun 2030 --> Sep 2029 | Trial primary completion date: Oct 2027 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    17d
    BGB-16673-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (2024-516234-35-00)
    P1/2, N=99, Recruiting, BeOne Medicines AG
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Lunsumio (mosunetuzumab-axgb) • sonrotoclax (BGB-11417) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    17d
    BGB-11417-303CLL-RR1: A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2024-517131-52-00)
    P2/3, N=285, Recruiting, BeOne Medicines AG
    New P2/3 trial
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab) • sonrotoclax (BGB-11417)
    22d
    ALLG NHL43: An open-label multi-centre international phase 2 trial to evaluate the safety and efficacy of two years fixed duration therapy with sonrotoclax in combination with the BGB-16673 and rituximab in patients with treatment naïve or BTKi naïve/intolerant Waldenström Macroglobulinemia (WM). (ACTRN12626000174381)
    P2, N=80, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New P2 trial
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Rituxan (rituximab) • sonrotoclax (BGB-11417) • catadegbrutinib (BGB-16673)
    26d
    Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches. (PubMed, Front Pharmacol)
    Main Findings: BCL2 inhibitors like venetoclax have achieved high response rates (ORR >70%) in CLL and AML but face resistance via MCL1/BCL-XL upregulation. Next-generation agents (e.g., sonrotoclax) and combinations address this...These strategies represent a paradigm shift toward precision medicine, but challenges like toxicity and biomarker-driven resistance persist. Future directions include AI-guided predictions and novel degraders like proteolysis-targeting chimeras (PROTACs).
    Review • Journal • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
    |
    Venclexta (venetoclax) • sonrotoclax (BGB-11417)
    29d
    A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    1m
    An Open-Label, Single-Arm Study of Sonrotoclax Plus Zanubrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without Disease Progression After First-Line BTK Inhibitor Therapy. (ChiCTR2500111878)
    P=N/A, N=50, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    2ms
    Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Canadian Cancer Trials Group
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    2ms
    Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • dexamethasone • sonrotoclax (BGB-11417)
    2ms
    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL (clinicaltrials.gov)
    P3, N=466, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)